70% less dementia. The statin data APOE4 carriers need to see

Hi Phoenix friend,

Your lipid panel was designed for the average person.

You're not the average person.

If you carry APOE4, your body processes lipids differently. Your brain clears cholesterol less efficiently. You form vascular disease more readily. And the targets your doctor considers "normal" might be leaving you dangerously exposed.

Part of our Monthly Q&A with experts in APOE4, we sat down with Dr. Grant Fraser (board-certified in anti-aging and regenerative medicine, 29 years of clinical experience, and an APOE4 carrier himself) for a deep dive into everything lipid-related for our community.

This isn't theory. This is what he does with patients every week.

Here are the biggest takeaways.

Forget Your Standard Lipid Panel

Dr. Fraser doesn't use the standard lipid panel to make treatment decisions. He orders it for "historical interest" only.

What he actually tracks: ApoB (the atherogenic particle count), Lp(a) (genetic and largely fixed), and whether you have actual vascular disease present.

The standard LDL number? Not useful enough. There's a 15% discordance between LDL-C and ApoB in the general population. When you can measure the real thing (ApoB, roughly $18 per test), why estimate?

His advice: if you can't access ApoB where you are, use non-HDL cholesterol as a proxy. You can even run it through an AI tool to get an estimated ApoB. Not perfect. But better than LDL alone.

His Exact ApoB Targets (by Genotype)

This is where it gets specific.

For someone with zero risk factors (3/3 genotype, Lp(a) negative, no vascular disease), Dr. Fraser likes ApoB in the 70s.

Then you start subtracting:

APOE 2/4: subtract roughly 5 from the goal.
APOE 3/4: subtract 10.
APOE 4/4: subtract 15.
Lp(a) positive (above 75): subtract another 20.
Established vascular disease: subtract another 20.

Do the math for a 4/4 carrier with high Lp(a) and some existing disease, and you could be looking at an ApoB target in the teens. That's aggressive. And it's almost certainly going to require medication.

The Statin Data That Changes the Debate

Dr. Fraser is firmly pro-statin for APOE4 carriers. And the data backs him up.

A Mendelian randomization study (which removes the confounding effects of lifestyle by looking at people born with a genetic "statin effect") found that those with the HMG-CoA reductase mutation had only 30% the rate of dementia compared to those without. That's a roughly 70% reduction [1].

A separate study specifically isolating APOE4 carriers on statins found a 40% reduction in dementia diagnosis over approximately five years [2].

The most interesting finding? In that same trial, non-APOE4 carriers on statins saw zero dementia benefit. The intervention was only significant for carriers.

Side effects affect about 5% of people. And Dr. Fraser notes that many of those are dose-related. His starting point is often remarkably low: rosuvastatin 5mg, Monday-Wednesday-Friday. One of his patients dropped ApoB from 111 to 70 with just that.

Lipophilic vs. Hydrophilic: The Brain Cholesterol Paradox

This is where it gets genuinely complicated.

Some statins cross the blood-brain barrier (lipophilic: atorvastatin). Others don't (hydrophilic: rosuvastatin).

One school of thought (Dr. Niotis, Dr. Dayspring): keep cholesterol high in the brain by using hydrophilic statins that stay out. The brain needs cholesterol. Lowering it there might cause problems.

The counter-argument: the Mendelian randomization data involved people whose genetic mutation affected ALL tissues, including the brain. They had the equivalent of a statin running in their brain from birth. And they had 70% less dementia.

Dr. Fraser's current approach: rotate monthly. One month atorvastatin. One month rosuvastatin. Hedge the uncertainty.

Is this the "right" answer? Maybe not. But it's an honest one. And it reflects how medicine actually works when the data is still evolving.

Ezetimibe, Bempedoic Acid, and PCSK9 Inhibitors

Dr. Fraser's escalation ladder looks like this:

Step 1: Low-dose statin (first line, cheap, effective, well-tolerated).
Step 2: Add ezetimibe (blocks cholesterol reabsorption in the gut, well-tolerated, cheap, stacks well with statins).
Step 3: Bempedoic acid if needed (good efficacy but expensive in the US, Canadian pharmacy workaround possible).
Step 4: PCSK9 inhibitors for cases needing very aggressive targets or statin intolerance (very effective but cost remains a barrier).

One interesting nuance on ezetimibe: the Mendelian randomization for the NPC1L1 gene (ezetimibe's target) showed an 80%+ risk reduction in dementia for those born with that mutation. But the mutation affects all tissues (including the brain), while the actual drug ezetimibe doesn't cross the blood-brain barrier. So the human benefit might not match the genetic signal. Mouse models look promising. Human certainty? Not yet.

Dr. Fraser's philosophy: "Add ezetimibe. It's cheap, benign, and if it turns out to have even part of that brain benefit, you've won. If not, your lipids are still better."

Diet: The Practical Protocol

Dr. Fraser's dietary framework for APOE4 carriers:

30 different plants per week (vegetables, nuts, seeds, fruits). Diversity drives gut health. Gut health drives brain health through the gut-brain axis.

30 grams of fiber daily (minimum). The average American gets 8 grams. Fiber binds cholesterol in the gut, preventing reabsorption. It also helps with estrogen metabolism in women.

Saturated fat below 5-6% of total calories. APOE4 carriers (especially 4/4s) tend to be hyper-responders to saturated fat. But measure the effect on yourself. Some people aren't. Personalize.

Source matters. Saturated fat from coconut oil or olive oil (with its antioxidants) is probably less harmful than from dairy or beef.

Pescatarian wins. Dr. Fraser's father runs the Adventist Health Study, which found pescatarians lived 11 years longer than the average Californian. The best outcome for both lifespan and brain health: whole food plant-based diet, add fish, maybe a little fermented dairy.

Supplements That Actually Move the Needle

Dr. Fraser's take on lipid-relevant supplements:

Omega-3s: improve triglycerides, probably help the brain. Small wild-caught fish is the most reliable delivery method (we KNOW it crosses into the brain). Supplements are less certain.

Berberine: 10-20% LDL decrease on average. Variable response. Worth trying.

Citrus bergamot: 10-15% decrease. Reasonable add-on.

Plant sterols: 8-10% LDL decrease. Minor but real.

Red yeast rice: AVOID. It's essentially unregulated lovastatin (one of the weakest, least-tolerated statins). Many products are contaminated with citrinin, which is toxic to your kidneys and liver. If you want a statin, get a real one.

Niacin: raises HDL. But HDL isn't "good cholesterol" (there's no evidence HDL levels affect outcomes). Skip this for lipid purposes.

Psyllium husk: fine as a supplement, but it's a missed opportunity. Get your fiber from actual food (heirloom beans, colored vegetables, berries) because you get the fiber PLUS hundreds of other beneficial compounds. Extracting one nutrient from the matrix rarely works as well.

The Test You Might Be Missing

Dr. Fraser's parting advice was the most urgent.

You can optimize every supplement, hit every ApoB target, and run every experiment. But if you haven't checked whether you already have vascular disease, you're optimizing in the dark.

APOE4 carriers are more likely to have coronary artery disease and cerebrovascular disease than the general population. Some people with "bad" lipids have zero disease. Others with "acceptable" lipids have critical disease.

The tests: CT coronary angiogram (preferably with CLEARLY analysis or cellular plaque analysis) and an MRA of the head and neck. There's a cost. But knowing your baseline changes your entire treatment strategy.

About Dr. Grant Fraser

Board Certified: American Board of Anti-Aging and Regenerative Medicine, with fellowship modules in Cardiology, Endocrine and Gastroenterology. Board Certified American Board of Family Medicine. Fellow of the Australian College of Rural and Remote Medicine with Advanced Specialty Training in Emergency Medicine and Generalist Emergency Medicine Post Fellowship Certification. Fellow of the Australian College of General Practitioners. 29 years of experience in Emergency Medicine and Rural Generalist Medicine.

He's also an APOE4 carrier and member of the Phoenix Community.

About The Phoenix Community

The Phoenix is the world's first precision health platform built for APOE4 carriers. We combine biomarker tracking, structured experiments, expert access, and a community of people who understand what it means to carry this gene.

If this conversation resonated with you, we'd love to have you.

👉 Join the Phoenix Community: https://thephoenix.community
🩸 Blood work blueprint: https://apoe4.co/bloodtest

Most Newsletters? One-way street.
How boring…
This is the Phoenix Community. So let's make it a two-way street.
Got a question? Feedback?
Hit reply. I read every single one.